HC Wainwright Lowers Co-Diagnostics (NASDAQ:CODX) Price Target to $9.00

Co-Diagnostics (NASDAQ:CODXGet Rating) had its price objective cut by HC Wainwright from $12.00 to $9.00 in a report released on Monday morning, The Fly reports. They currently have a buy rating on the stock.

Separately, Sidoti cut shares of Co-Diagnostics from a buy rating to a neutral rating and set a $5.00 price target on the stock. in a report on Friday, August 12th.

Co-Diagnostics Stock Down 2.6 %

CODX stock opened at $3.76 on Monday. Co-Diagnostics has a twelve month low of $3.58 and a twelve month high of $11.44. The stock has a market capitalization of $127.02 million, a price-to-earnings ratio of 4.22 and a beta of -1.60. The firm’s fifty day simple moving average is $5.70 and its two-hundred day simple moving average is $5.63.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CODX. Janney Montgomery Scott LLC grew its holdings in shares of Co-Diagnostics by 86.9% in the fourth quarter. Janney Montgomery Scott LLC now owns 37,970 shares of the company’s stock worth $339,000 after purchasing an additional 17,650 shares during the last quarter. Advisor Group Holdings Inc. lifted its stake in Co-Diagnostics by 142.9% in the fourth quarter. Advisor Group Holdings Inc. now owns 31,199 shares of the company’s stock worth $278,000 after acquiring an additional 18,353 shares during the period. American Century Companies Inc. purchased a new stake in Co-Diagnostics in the fourth quarter worth about $571,000. First Trust Advisors LP lifted its stake in Co-Diagnostics by 14.1% in the fourth quarter. First Trust Advisors LP now owns 44,053 shares of the company’s stock worth $393,000 after acquiring an additional 5,457 shares during the period. Finally, Lazard Asset Management LLC lifted its stake in Co-Diagnostics by 21.7% in the fourth quarter. Lazard Asset Management LLC now owns 9,837 shares of the company’s stock worth $87,000 after acquiring an additional 1,754 shares during the period. 21.00% of the stock is currently owned by institutional investors.

About Co-Diagnostics

(Get Rating)

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications.

Featured Articles

The Fly logo

Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.